Compare IPWR & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPWR | TELA |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.8M | 51.2M |
| IPO Year | 2013 | 2019 |
| Metric | IPWR | TELA |
|---|---|---|
| Price | $3.87 | $1.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $10.75 | $3.31 |
| AVG Volume (30 Days) | 70.1K | ★ 356.9K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $43,136.00 | ★ $77,055,000.00 |
| Revenue This Year | N/A | $18.39 |
| Revenue Next Year | $3,233.33 | $15.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.24 |
| 52 Week Low | $3.06 | $0.86 |
| 52 Week High | $8.62 | $3.10 |
| Indicator | IPWR | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 43.63 | 43.78 |
| Support Level | $4.05 | $1.10 |
| Resistance Level | $4.50 | $1.21 |
| Average True Range (ATR) | 0.39 | 0.07 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 55.04 | 21.11 |
Ideal Power Inc is pioneering the development of its broadly patented bidirectional power switches, creating efficient and ecofriendly energy control solutions for electric vehicles, electric vehicle charging, renewable energy, energy storage, UPS / data center, solid-state circuit breaker and other industrial and military applications. The company is focused on its patented Bidirectional, Bipolar Junction Transistor (B-TRAN) semiconductor technology. B-TRAN is a double-sided bidirectional AC switchable to deliver substantial performance improvements over conventional power semiconductors. The primary raw material used in the fabrication of B-TRAN devices is silicon wafers.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.